B-Cell Lymphoma Clinical Trial
Official title:
A Phase 1 Multi-Center, Dose Escalation and Pharmacokinetic Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma
NCT number | NCT00316511 |
Other study ID # | C-726-05 |
Secondary ID | |
Status | Completed |
Phase | Phase 1 |
First received | April 19, 2006 |
Last updated | October 24, 2008 |
Start date | March 2006 |
Verified date | October 2008 |
Source | Agenus, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is a dose escalation study. Patients will be enrolled in cohorts of three patients each, and escalation of dose to the next cohort will be determined based on dose-limiting toxicity (DLT) in the previous cohort. This study aims to identify the maximum tolerated dose (MTD) of intravenous L-NDDP. Once the MTD has been determined, an additional four patients will be enrolled at that dose level. While the MTD is determined based on safety data from each cohort's first cycle of L-NDDP therapy only, patients may continue treatment with additional cycles of L-NDDP at the same dose as their starting dose until documented progression, unacceptable toxicity, or another off study criterion is met. Patients who have not met any of the off study criteria and continue to receive L-NDDP therapy at the time when MTD is determined may be allowed to change L-NDDP dose to the MTD dose level. The study will also determine the pharmacokinetic profile of L-NDDP administration. Clinical activity of L-NDDP in solid tumor patients will be assessed as tumor response using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Clinical activity of L-NDDP in B-cell lymphoma patients will be assessed using the International Working Group recommendations.
Status | Completed |
Enrollment | 21 |
Est. completion date | |
Est. primary completion date | June 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Advanced solid malignancies or B-cell lymphoma 2. Less than or equal to 5 anti-cancer treatment regimens, which must be concluded at least four weeks prior to the first planned L-NDDP administration 3. Measurable disease 4. Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 5. New York Heart Association (NYHA) Class I or II 6. Greater than or equal to 18 years of age 7. Absolute neutrophil count greater than or equal to 1.5 x 10^9/L 8. Platelets greater than or equal to 100 x 10^9/L 9. Creatinine less than or equal to 1.5 x upper limit of normal (ULN) 10. ALT less than 3 x ULN in absence of liver metastases; less than 5 x ULN in presence of liver metastases. 11. Hemoglobin greater than or equal to 10 g/dL 12. Total bilirubin less than or equal to 2 x ULN 13. Female of childbearing potential must have a negative serum pregnancy test 14. Male or female patients of child producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for one month after the last L-NDDP dose. 15. Signed written informed consent must be obtained and documented according to ICH-GCP, the local regulatory requirements, and the rules followed at each institution. Exclusion Criteria: 1. Known active or untreated brain metastases 2. Other ongoing systemic cancer therapies 3. Hypersensitivity to platinum compounds 4. Other active malignancies with the exception of adequately treated in-situ carcinoma of the uterine cervix, or non-melanoma skin cancer 5. A marked baseline prolongation of QT/QTc interval (e.g. repeated demonstration [at least two assessments at a minimum of 48 hours apart] of a QTc interval of > 450 for males and > 470 for females) or history of additional risk factors for torsades des pointes or use of concomitant medication prolonging the QT/QTc interval 6. Serious illness which, in the opinion of the Principal Investigator, would prevent study completion 7. Investigational therapy currently or within four weeks prior to planned first dose of L-NDDP 8. Women who are pregnant or breastfeeding will be excluded from participation. |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Agenus, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determine the maximum tolerated dose and dose-limiting toxicity of L-NDDP | |||
Primary | Assess safety of L-NDDP | |||
Primary | Determine the pharmacokinetic profile of L-NDDP | |||
Secondary | Assess clinical activity |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05365659 -
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
|
Phase 1 | |
Withdrawn |
NCT05929716 -
An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Recruiting |
NCT05016947 -
Venetoclax Plus Inotuzumab for B-ALL
|
Phase 1 | |
Completed |
NCT02900716 -
Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas
|
Phase 1 | |
Completed |
NCT03068416 -
CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy
|
Phase 2 | |
Not yet recruiting |
NCT05014100 -
Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT05934838 -
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
|
Phase 1 | |
Terminated |
NCT04023071 -
FT516 in Subjects With Advanced Hematologic Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04148430 -
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
|
Phase 2 | |
Completed |
NCT02933320 -
BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03133221 -
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
|
Phase 2 | |
Completed |
NCT02741388 -
A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP
|
Phase 1 | |
Completed |
NCT02300402 -
Detection and Characterization of Residual Masses in Lymphomas
|
||
Terminated |
NCT02266147 -
Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
|
Phase 1/Phase 2 | |
Terminated |
NCT00906841 -
Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma
|
Phase 2 | |
Completed |
NCT00338494 -
Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT05487651 -
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
|
Phase 1 | |
Withdrawn |
NCT05570188 -
Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT03281551 -
Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
|
Phase 1 |